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ORIGINAL ARTICLE
In response to certain physiologic signals or
pathologic processes, the renal tubular epithe-
lium undergoes periods of rapid growth involving
both hyperplasia and hypertrophy.1 In addition 
to epidermal growth factor and angiotensin II,
the endothelins (ETs) are now recognized to
function importantly as growth-promoting fac-
tors for the renal tubular epithelium.2,3 In renal
tissue, the ETs serve as both paracrine and auto-
crine growth factors.3 Three isoforms of ETs,
termed as ET-1, ET-2 and ET-3, have been iden-
tified that interact with two receptors, termed as
ETA and ETB. Both receptors are present in the 
kidney.4,5
The signal transduction pathways involved in
renal growth regulation are relatively complex.1,2,6
These pathways have been characterized for renal
mesangial cells but not for renal tubuloepithelial
cells. ET-1 stimulates renal mesangial cell prolifera-
gtion through several pathways, prominent amon
which are those involving the mitogen-activated
protein kinases (MAPKs).7 ET-1 binds to the ETA
rreceptor, signals the activation of extracellula
signal-regulated kinase (ERK)1/2, and modulates
expression of the immediate early genes (c-fos, c-jun)
to induce proliferation of renal mesangial cells.7
Following a mitotic signal, cells undergo a
tfinely regulated series of changes in status tha
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together comprise the cell cycle. Progression from
G1 into S phase is determined at the restriction
point and is governed by the activity of retinoblas-
toma (RB), the product of the RB gene. In its hypo-
phosphorylated state, RB is active and serves to
block progression to S phase. Upon phosphory-
lation, RB is inactivated such that progression
into S phase occurs.1 The cell cycle is ultimately
controlled by cell cycle-regulatory proteins. Transi-
tions between each phase of the cell cycle are
positively regulated by the kinase activity of a
distinct holoenzyme composed of two subunits:
the cyclins and their partners, the cyclin-dependent
kinases (CDKs). CDK inhibitors negatively regu-
late cell cycle progression, and subsequently arrest
the cell cycle, by inhibiting formation of CDK
complexes.8 In rat mesangial cells, cyclin D1-CDK
activity and the phosphorylation of RB mediate
the mitogenic response to ET-1.9
Epithelial and endothelial cells often utilize
similar signaling systems during the process of
tubulation. However, it is unclear whether growth
factors such as endothelin promote hyperplasia
of the renal mesangium and tubuloepithelium
through comparable mechanisms. Cultured opos-
sum kidney (OKP) cells, which are subcloned from
an opossum kidney cell line, exhibit many char-
acteristics of proximal tubuloepithelial cells and
therefore represent a useful in vitro model of these
cells.10 For example, ET-1 acutely increases Na/H
antiporter activity in OKP cells stably transfected
with ETB receptor cDNA and induces these ETB–
overexpressing cells to proliferate.11,12 The present
report describes the effects of ET-1 on the expres-
sion of immediate early genes, the activation state
of MAPKs, and the disposition of cell cycle regula-
tory proteins in ETB–overexpressing OKP cells.
Materials and Methods
Materials
Culture media, fetal bovine serum (FBS), and
trypsin-EDTA were obtained from Gibco (Grand
Island, NY, USA). Culture flasks and plates were
purchased from Corning (Corning, NY, USA).
Blocking reagent, alkaline phosphatase-conjugated
antidigoxigenin antibody, CSPD (chemilumines-
cent substrate alkaline phosphatase detection), and
digoxigenin-UTP (uridine triphosphate) were pur-
chased from Boehringer Mannheim (Mannheim,
Germany). The pGEM-dT vector was purchased
from Promega (Madison, WI, USA). Aprotinin,
phenylmethylsulfonyl fluoride (PMSF), and so-
dium orthovanadate were obtained from Sigma
(St. Louis, MO, USA). Bicinchoninic acid (BCA)
reagents were obtained from Pierce (Rockford,
IL, USA). Anti-phospho-ERK1/2, anti-ERK1/2,
anti-phospho-p38 MAPK, anti-p38 MAPK, anti-
phospho-MEK1/2, and anti-MEK1/2 were pur-
chased from New England Biolabs (Beverly, MA,
USA). BQ123, BQ788, and PD98059 were pur-
chased from Research Biochemicals International
(Natick, MA, USA). Anti-cyclin D1, anti-CDK4,
anti-RB, anti-Ser795-phosphorylated RB, and anti-
p27 were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Anti-actin was
obtained from Chemicon (Tamecula, CA, USA).
PVDF membranes were obtained from Millipore
(Bedford, MA, USA). Enhanced chemilumines-
cence (ECL) kits were obtained from Amersham
(Arlington Heights, IL, USA).
Cell culture
OKP cells overexpressing the ETB receptor (OKP
ETB6 clone) were provided by Dr Robert Alpern.11
The cells were propagated in high glucose (450
mg/dL) Dulbecco’s modified Eagle’s medium
(DMEM) with 10% FBS, penicillin (100 U/mL),
and streptomycin (100 μg/mL). For experimenta-
tion, cells were grown in low glucose (100 mg/dL)
DMEM. When confluent, cells were rendered qui-
escent by incubation for 48 hours in serum-free
medium.
RNA preparation and analysis
Total cellular RNA was extracted with guanid-
inium thiocyanate/phenol/chloroform and iso-
lated by ethanol precipitation.13 Twenty microgram
of total RNA were size-fractionated by agarose-
formaldehyde gel electrophoresis and transferred to
nylon membranes. RNA blots were hybridized
overnight at 65°C with antisense RNA probe in hy-
bridization solution composed of 50% formamide,
5X SSCP (1X SSCP is 120 mM NaCl, 15 mM so-
dium citrate, 13mM KH2PO4, and 1mM EDTA, pH
7.2), 0.1% sodium lauryl sarcosine, 2% sodium
dodecyl sulfate (SDS), and 5% blocking reagent.
Blots were then washed in 0.1X SSCP and 0.1%
SDS at 65°C and developed using alkaline phos-
phatase-conjugated antidigoxigenin antibody and
CSPD according to the manufacturer’s directions.
Probe synthesis
To synthesize the c-jun riboprobe for Northern blot
hybridization, a cDNA fragment of rat c-jun was first
amplified by the reverse transcription polymerase
chain reaction from glomerular RNA of Wistar rats
using the following specific primer pair: rat c-jun,
upstream, 5′-TTCTGAAGCAGAGCATGACC-3′ and
downstream, 5′-TTGAAGTTGCTGAGGTTGGC-3′
(GeneBank accession no. X17163). The amplified
products were eluted from acrylamide gels and
subcloned into the pGEM-dT vector. The antisense
RNA probe was transcribed using phage poly-
merase in the presence of digoxigenin-UTP from
subcloned templates.14
Protein extraction for Western blotting
Cultured cells were washed three times in 
phosphate-buffered saline (PBS), scraped into
RIPA buffer [150 mM NaCl, 50 mM tris(hydroxy-
methyl)aminomethane (TRIS) HCl, pH 7.4,
2.5 mM EDTA, 5 mM ethylene glycol-bis (β-
aminoethyl ether)-N,N,N′,N′-tetraacetic acid
(EGTA), 50 mM β-glycerophosphate, 50 mM NaF,
1mM sodium orthovanadate, 1mM PMSF, 0.5mM
dithiothreitol, 1% triton X-100, 1% sodium deoxy-
cholate, 0.1% SDS, 2 μg/mL aprotinin], incubated
at 4°C for 45 minutes, and centrifuged at 10,000g
for 15 minutes.
Supernatants were diluted with RIPA buffer,
and total protein contents were determined with
a BCA protein assay.
Measurement of ERK and MEK activities
The Western blotting analysis of ERK phospho-
rylation was performed with phospho-specific
antibodies according to the manufacturer’s pro-
 tocol. Briefly, OKP cells were stimulated with
ET-1 at different time points. Inhibitors (BQ788,
BQ123, and PD98059) were added to incuba-
tions 30 minutes prior to addition of ET-1.15,16
Cell lysates (50 μg protein) were subjected to
SDS-PAGE (10%) and proteins were then trans-
ferred to PVDF membrane. For immunodetection,
the membranes were probed with phospho-
specific ERK antibody (1:1000) followed by in-
ycubation with peroxidase-conjugated secondar
antibody (1:4000). Bands were visualized with
ECL system. MEK and p38 MAPK activities were
measured by a similar method.
Western blot analysis of cell cycle proteins
For Western blot analysis, 50 μ tg of protein extrac
were treated for 5 minutes at 100°C, and dena-
tured proteins were separated by 10% SDS-PAGE.
After electrophoresis, electroblotting onto PVDF
membranes was performed, and the blots were
stained with Coomassie blue to ensure complete
protein transfer. Blots were incubated in 1X PBS
containing 0.1% Tween-20 and 5% nonfat milk to
prevent nonspecific antibody binding. Blots were
then incubated for 2 hours at room temperature
with antibodies for cyclin D1, CDK4, RB, Ser795-
phosphorylated RB, or p27. Blots were washed in
0.1% Tween-20 in PBS for 15 minutes, re-washed
at least twice for 5 minutes, and incubated with
a 1:5000 dilution of horseradish peroxidase-
labeled anti-mouse IgG in 5% nonfat milk and
0.05% Tween-20 in PBS for 1 hour. Western blots
were developed by the ECL system.
Results
ET-1 increases c-jun mRNA abundance
tAs shown in Figure 1A, treatment with ET-1 a
10 nM ET-1 increased c-jun mRNA abundance in
ETB–overexpressing OKP cells. This effect was de-
tectable at 15 minutes and maximal at 30 minutes,
and an optimal increase in message of approxi-
fmately 10-fold was observed. After 30 minutes o
treatment, c-jun mRNA abundance decreased to
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approach basal values. The dose-response relation-
ship for this effect of ET-1 is shown in Figure 1B.
Threshold and peak responses were 1 and 10 nM
ET-1, respectively.
MAPK activation in response to ET-1
ET-1 treatment enhanced ERK1/2 activity in a dose-
dependent manner with threshold and peak re-
sponses of 1 and 10nM ET-1, respectively, observed
(Figure 2A). The maximal stimulation of ERK
phosphorylation by ET-1 was approximately 8-fold
as compared with that in control preparations.
The time dependence for ET-1-dependent ERK1/2
phosphorylation is illustrated in Figure 2B. Phos-
phorylation of ERK1/2 was increased within 1
minute and was maximal at 5–10 minutes. In con-
trast, the activity of p38 MAPK was not enhanced
by ET-1 in these cells (data not shown).
Effects of BQ788, BQ123, and PD98059 on
ET-1-stimulated ERK1/2 phosphorylation
Because these studies were performed with ETB
receptor–overexpressing cells, it was probable that
observed effects of ET-1 were mediated by the ETB
receptor. Antagonists selective for the ETA or ETB
receptor were therefore employed to validate this
assumption. ET-1-induced ERK1/2 phosphory-
flation was significantly reduced in the presence o
10−7 M BQ788, an ETB-selective blocker, but was
unaffected in the presence of 10−7 M BQ123, an
ETA-selective blocker (Figure 3A). ERK1/2 phos-
phorylation in response to ET-1 was also reduced
significantly in the presence of 10−5 M PD98059,
an inhibitor of MEK (Figure 3B).
MEK1/2 phosphorylation in response to ET-1
t As shown in Figure 4, ET-1 (10 nM) treatmen
increased MEK1/2 activity in ETB g–overexpressin
fOKP cells. An increase in phosphorylation o
MEK1/2 was observed within 1 minute and was
fmaximal at 5 minutes. The optimal stimulation o
phosphorylation was approximately 8-fold. rAfte
5 minutes, MEK1/2 phosphorylation was observed
to decrease to approach basal values.
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iF gure 1. Endothelin-1 (ET-1) increases c-jun mRNA abun-
dance in ETB–overexpressing OKP cells. (A) Time course
with 10 nM ET-1. (B) Dose response at 30 minutes. Results
shown are typical of three separate experiments. C=control;
FBS = fetal bovine serum.
p-MEK1/2
MEK1/2
Time (min) C 1 5 10 30 60
iF gure 4. d h l ( ) kEn ot e in-1 ET-1  increases MAPK inase
(MEK1/2) phosphorylation in ETB–overexpressing OKP cells.
Results shown are typical of three separate experiments.
C=control.
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iF gure 2. Endothelin-1 (ET-1) increases extracellular signal-
regulated kinase (ERK1/2) phosphorylation in ETB–over-
expressing OKP cells. (A) Dose response at 10 minutes.
(B) Time course with 10 nM ET-1. Results shown are typi-
cal of three separate experiments. C = control.
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iF gure 3. Endothelin-1 (ET-1) induced-ERK1/2 phosphory-
lation is mediated by ETB receptor and MAPK kinase (MEK).
(A) Cells were treated with 10nM ET in absence or presence
of BQ788, an ETB-selective blocker, or BQ123, an ETA-
selective blocker. (B) Cells were treated with 10 nM ET in
absence or presence of PD98059, an MEK inhibitor. Results
shown are typical of three separate experiments. C=control.
Disposition of cell cycle proteins in 
ET-1-treated ETB–overexpressing OKP cells
Treatment with 10 nM ET-1 resulted in a 2-fold
increase in cyclin D1 expression in these cells,
with maximal stimulation observed at 4 hours.
In the lane of 12 hours, there is very minimal in-
duction (Figure 5). However, expression of
CDK4 was not enhanced under these conditions
(data not shown). As shown in Figure 6, 10 nM
ET-1 also induced a 2-fold increase in RB phos-
phorylation, with maximal effects also observed at
4 hours. In the lane of 24 hours, there is decrease
in the phosphorylation levels of RB. However, ET-1
did not alter the expression of p27 in these cells
(data not shown).
Discussion
Although ET-1 has been shown to induce hyper-
plasia in ETB–overexpressing OKP cells,12 the sig-
naling mechanisms through which hyperplasia is
induced were previously unknown. The present
study provides evidence that ET-1 signals the acti-
vation of MEK1/2 and ERK1/2, an increase in
immediate early gene (c-jun) expression, the
modulation of cyclin D1, and an increase in RB
phosphorylation in these cells. These events are
likely to be relevant to those in normal renal tubu-
lar epithelial cells. The effects of ET-1 at the renal
tubule are thought to be mediated mainly by the
ETB receptor whereas those at the renal glomerular
mesangium are known to be mediated by the ETA
receptor. Endothelin has been shown to bind to
S1 proximal tubule cells, with ET-1 and ET-3
binding occurring at similar magnitudes, consis-
tent with the presence of the ETB receptor in
these cells.17 Findings of the present study with
ETB–overexpressing OKP cells are consistent with
involvement of the ETB creceptor in the mitogeni
effects of ET-1 at the renal tubular epithelium. In
particular, ET-1-dependent ERK1/2 activation in
the OKP cells was reduced by ETB r-selective recepto
blockade.
yThe protein products of the immediate earl
genes c-fos and c-jun function cooperatively as the
components of the mammalian transcription
factor activator protein (AP)-1 to induce cell pro-
liferation.18 Consistent with involvement of the
immediate early genes in the actions of ET-1 in
ETB–overexpressing OKP cells, ET-1 was observed
to increase c-jun mRNA abundance to maximal
degrees within 30 minutes. Endothelin increases
c-fos mRNA and c-jun tmRNA abundance in ra
mesangial cells to similar degrees and over com-
parable time periods.19
MAPKs can be divided into three broad fami-
lies on the basis of sequence similarity, upstream
activators, and substrate specificity.20 cThe classi
extracellular signal-regulated kinases (ERKs: ERK1
gand ERK2) are recognized to function durin
growth factor-related signaling, whereas the jun
NH2-terminal kinase (JNK) and p38 families are
known to be activated during cellular responses
to stress and inflammation.20 ET-1 (10 nM) was
found to activate ERK1/2, but not p38, in ETB–
overexpressing OKP cells. This selective activation
of ERK is not surprising in that ET-1, a growth
rfactor, is known to signal ERK activation in othe
tissues.7,21 ET-1 rapidly activates ERK1/2 in renal
mesangial cells but higher concentrations of the
factor (100 nM) are required.22,23 The high concen-
tration of ETB rreceptors in the cells selected fo
the present study may explain this discrepancy.
Alternatively, the inconsistency may be attribu-
table to differences in receptor and/or cell type.
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Cyclin D1
Actin
Time (hr) C 4 8 12 24
iF gure 5. Endothelin-1 (ET-1) increases cyclin D1 expres-
sion in ETB–overexpressing OKP cells. Results shown are
typical of three separate experiments. C = control.
p-Rb
Rb
Time (hr) C 4 8 12 24
iF gure 6. Endothelin-1 (ET-1) increases retinoblastoma gene
product (RB) phosphorylation in ETB–overexpressing OKP
cells. Results shown are typical of three separate experi-
ments. C = control; pRB = hyperphosphorylated form of RB.
MEKs are upstream activators of MAPK. Accor-
dingly, ET-1 was found to promote activation of
MEK1/2 in ETB–overexpressing OKP cells, with 
a maximal response occurring within 5 minutes.
Comparable signaling of MEK activation is also
observed in rat glomerular mesangial cells in
response to ET-1.24
The proteins cyclin D1 and CDK4 regulate the
cell cycle at G1 in a positive manner.8 ET-1 signaled
the activation of cyclin D1 and phosphorylation of
RB in ETB–overexpressing OKP cells without affect-
ing the activity of CDK4 or p27. These findings dif-
fer from those in rat mesangial cells where ET-1
was found to increase both cyclin D1 expression
and CDK4 activity via the ETA receptor.9 These
effects are regulated by the expression of cyclin D1,
p16, p21, and phosphorylatable form of RB.9 It is
clear, therefore, that the early mitogenic effects of
ET-1 in renal tubuloepithelial cells are similar, but
not identical, to those in renal mesangial cells.
Additionally, the mitogenic actions of endothelin
in rat mesangial cells are proposed to involve
stimulations of phospholipase C activity, Na+/H+
exchange, and c-fos expression.25 Whether such
signaling events are required for ET-1-dependent
induction of renal tubular epithelial hyperplasia
is unclear.
The ET-1-dependent signaling events identi-
fied in the present study may operate during devel-
opment of renal failure. Progressive renal failure
results from a triad of glomerulosclerosis, tubulo-
interstitial fibrosis, and vascular sclerosis.26,27 After
a loss of functioning nephrons, the remaining glo-
meruli and tubules become hypertrophic through
the action of various growth factors and/or vasoac-
tive substances such as endothelin.27 These reac-
tions ultimately result in glomerulosclerosis and
tubulointerstitial fibrosis.2,27 A close association
exists between the progression of chronic renal
disease and structural derangements of the tubulo-
epithelial compartment.28 Renal tubule cell hyper-
plasia and hypertrophy are both regarded as
antecedents of tubulointerstitial fibrosis.2 It is
of particular interest that activation of the ERK
pathway has been found to precede tubular 
proliferation in the obstructed rat kidney.29
Pentoxifylline inhibits platelet derived growth
factor-stimulated mesangial cell proliferation
through attenuated cyclin D1 expression and de-
creased RB phosphorylation.30 Pentoxifylline and
dipyridamole have renoprotective effect. Recently,
we found that pentoxifylline and dipyridamole
inhibited OKP cell proliferation.31 Dipyridamole
inhibits platelet derived growth factor-stimulated
human peritoneal mesothelial cell proliferation
through attenuated extracellular signal-regulated
protein kinase activity, preservation of p27, and
decreased RB phosphorylation.32
Endothelin-1 transgenic mice develop glome-
rulonephrosis, interstitial fibrosis, and renal cysts
but not hypertension.33 In this study, we demon-
strated that ETB-selective blocker inhibited ET-1
induced MAPK activation, which was the under-
lying signaling mechanism of cell proliferation.
Renal protection of ET antagonists was mediated
by both glomerular and tubular action. Bosentan,
a nonselective ET antagonist, attenuates renal in-
tjury and prolongs survival in rats with remnan
kidney.34 Bosentan has been used for essential
hypertension and pulmonary hypertension.35,36
ERKs mediate cellular functions other than cell
proliferation. In OKP cells, ET-1 acutely increased
Na/H exchanger-3 (NHE-3) activity through Ca-
dependent pathway and tyrosine kinase path-
way.11,37 AAcid incubation increases NHE-3 mRN
abundance in OKP cells.38 Acid-induced activation
of NHE3 is mediated by c-SRC and ERK.39
tIn conclusion, ET-1 was observed to interac
with the ETB receptor to activate both MEK1/2
and ERK1/2, to increase expression of c-jun r, to alte
the disposition of cyclin D1, and to increase RB
phosphorylation in these cells. These signals are
therefore proposed to mediate the proliferative
effects of the growth factor on renal tubuloepi-
thelial cells.
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